166 related articles for article (PubMed ID: 29755980)
1. Importance of Validating Antibodies and Small Compound Inhibitors Using Genetic Knockout Studies-T Cell Receptor-Induced CYLD Phosphorylation by IKKε/TBK1 as a Case Study.
Lork M; Kreike M; Staal J; Beyaert R
Front Cell Dev Biol; 2018; 6():40. PubMed ID: 29755980
[TBL] [Abstract][Full Text] [Related]
2. Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL).
Xu X; Kalac M; Markson M; Chan M; Brody JD; Bhagat G; Ang RL; Legarda D; Justus SJ; Liu F; Li Q; Xiong H; Ting AT
Cell Death Dis; 2020 Feb; 11(2):94. PubMed ID: 32024820
[TBL] [Abstract][Full Text] [Related]
3. Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD.
Zhang M; Wu X; Lee AJ; Jin W; Chang M; Wright A; Imaizumi T; Sun SC
J Biol Chem; 2008 Jul; 283(27):18621-6. PubMed ID: 18467330
[TBL] [Abstract][Full Text] [Related]
4. Identification of TBK1 and IKKε, the non-canonical IκB kinases, as crucial pro-survival factors in HTLV-1-transformed T lymphocytes.
Zhang H; Chen L; Cai SH; Cheng H
Leuk Res; 2016 Jul; 46():37-44. PubMed ID: 27123832
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of TBK1/IKKε blunts immunopathology in a murine model of SARS-CoV-2 infection.
Ullah TR; Johansen MD; Balka KR; Ambrose RL; Gearing LJ; Roest J; Vivian JP; Sapkota S; Jayasekara WSN; Wenholz DS; Aldilla VR; Zeng J; Miemczyk S; Nguyen DH; Hansbro NG; Venkatraman R; Kang JH; Pang ES; Thomas BJ; Alharbi AS; Rezwan R; O'Keeffe M; Donald WA; Ellyard JI; Wong W; Kumar N; Kile BT; Vinuesa CG; Kelly GE; Laczka OF; Hansbro PM; De Nardo D; Gantier MP
Nat Commun; 2023 Sep; 14(1):5666. PubMed ID: 37723181
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Hutti JE; Shen RR; Abbott DW; Zhou AY; Sprott KM; Asara JM; Hahn WC; Cantley LC
Mol Cell; 2009 May; 34(4):461-72. PubMed ID: 19481526
[TBL] [Abstract][Full Text] [Related]
7. Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε.
Hutti JE; Porter MA; Cheely AW; Cantley LC; Wang X; Kireev D; Baldwin AS; Janzen WP
PLoS One; 2012; 7(7):e41494. PubMed ID: 22859992
[TBL] [Abstract][Full Text] [Related]
8. DDX19 Inhibits Type I Interferon Production by Disrupting TBK1-IKKε-IRF3 Interactions and Promoting TBK1 and IKKε Degradation.
Zhang K; Zhang Y; Xue J; Meng Q; Liu H; Bi C; Li C; Hu L; Yu H; Xiong T; Yang Y; Cui S; Bu Z; He X; Li J; Huang L; Weng C
Cell Rep; 2019 Jan; 26(5):1258-1272.e4. PubMed ID: 30699353
[TBL] [Abstract][Full Text] [Related]
9. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK epsilon.
Harris J; Olière S; Sharma S; Sun Q; Lin R; Hiscott J; Grandvaux N
J Immunol; 2006 Aug; 177(4):2527-35. PubMed ID: 16888014
[TBL] [Abstract][Full Text] [Related]
10. Activation of TBK1 and IKKvarepsilon kinases by vesicular stomatitis virus infection and the role of viral ribonucleoprotein in the development of interferon antiviral immunity.
tenOever BR; Sharma S; Zou W; Sun Q; Grandvaux N; Julkunen I; Hemmi H; Yamamoto M; Akira S; Yeh WC; Lin R; Hiscott J
J Virol; 2004 Oct; 78(19):10636-49. PubMed ID: 15367631
[TBL] [Abstract][Full Text] [Related]
11. Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages.
Solis M; Romieu-Mourez R; Goubau D; Grandvaux N; Mesplede T; Julkunen I; Nardin A; Salcedo M; Hiscott J
Eur J Immunol; 2007 Feb; 37(2):528-39. PubMed ID: 17236232
[TBL] [Abstract][Full Text] [Related]
12. Transient blockade of TBK1/IKKε allows efficient transduction of primary human natural killer cells with vesicular stomatitis virus G-pseudotyped lentiviral vectors.
Chockley P; Patil SL; Gottschalk S
Cytotherapy; 2021 Sep; 23(9):787-792. PubMed ID: 34119434
[TBL] [Abstract][Full Text] [Related]
13. IKKε and TBK1 prevent RIPK1 dependent and independent inflammation.
Eren RO; Kaya GG; Schwarzer R; Pasparakis M
Nat Commun; 2024 Jan; 15(1):130. PubMed ID: 38167258
[TBL] [Abstract][Full Text] [Related]
14. MAVS activates TBK1 and IKKε through TRAFs in NEMO dependent and independent manner.
Fang R; Jiang Q; Zhou X; Wang C; Guan Y; Tao J; Xi J; Feng JM; Jiang Z
PLoS Pathog; 2017 Nov; 13(11):e1006720. PubMed ID: 29125880
[TBL] [Abstract][Full Text] [Related]
15. SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways.
Huang J; Liu T; Xu LG; Chen D; Zhai Z; Shu HB
EMBO J; 2005 Dec; 24(23):4018-28. PubMed ID: 16281057
[TBL] [Abstract][Full Text] [Related]
16. The non-canonical IκB kinases IKKε and TBK1 as potential targets for the development of novel therapeutic drugs.
Niederberger E; Möser CV; Kynast KL; Geisslinger G
Curr Mol Med; 2013 Aug; 13(7):1089-97. PubMed ID: 23157677
[TBL] [Abstract][Full Text] [Related]
17. Chrysin modulates protein kinase IKKε/TBK1, insulin sensitivity and hepatic fatty infiltration in diet-induced obese mice.
Amir Siddiqui M; Badruddeen ; Akhtar J; Uddin S; Chandrashekharan SM; Ahmad M; Khan MI; Khalid M
Drug Dev Res; 2022 Feb; 83(1):194-207. PubMed ID: 34350600
[TBL] [Abstract][Full Text] [Related]
18. Differential requirement of IKK2 for CYLD-dependent representation of thymic and peripheral T-cell populations.
Tsagaratou A; Grammenoudi S; Mosialos G
Eur J Immunol; 2011 Oct; 41(10):3054-62. PubMed ID: 21728169
[TBL] [Abstract][Full Text] [Related]
19. IKKε and TBK1 expression in gastric cancer.
Lee SE; Hong M; Cho J; Lee J; Kim KM
Oncotarget; 2017 Mar; 8(10):16233-16242. PubMed ID: 27145266
[TBL] [Abstract][Full Text] [Related]
20. Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
Lefranc J; Schulze VK; Hillig RC; Briem H; Prinz F; Mengel A; Heinrich T; Balint J; Rengachari S; Irlbacher H; Stöckigt D; Bömer U; Bader B; Gradl SN; Nising CF; von Nussbaum F; Mumberg D; Panne D; Wengner AM
J Med Chem; 2020 Jan; 63(2):601-612. PubMed ID: 31859507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
